An in-house cohort comprising 185 patients of advanced NSCLC treated with PD-1/PD-L1 immunotherapy alone or in combination with chemotherapy was deployed to verify the prognostic impact of mutant KEAP1/STK11. The gene discussed is STK11; the disease is non-small cell lung carcinoma.